Research programme: telomerase inhibitors - Antisoma

Drug Profile

Research programme: telomerase inhibitors - Antisoma

Alternative Names: AS 1410; BRACO 19; Telomere targeting agents

Latest Information Update: 15 Mar 2010

Price : $50

At a glance

  • Originator Cancer Research UK
  • Developer Antisoma; Cancer Research UK
  • Class
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 09 Dec 2005 Antisoma has decided not to advance AS 1410 to clinical development due to unacceptable toxicity
  • 03 Jun 2005 Antisoma has signed an agreement with Heraeus so that the latter company will provide supplies of AS 1410 for clinical trials
  • 05 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top